An Andalusian team of researchers led by the University of Granada has demonstrated the efficacy of a new drug against cancerogenic stem cells, which cause the onset and development of cancer, of...
Common indigestion medicine could be used in fight against cancer
11/27/2014
According to a new study, a common medicine used to treat indigestion can also improve survival rates in colorectal cancer cases and other forms of the disease.
The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer.
Researchers stop 'vicious cycle of inflammation' that leads to tumor growth
11/27/2014
UAlberta research team finds that inhibiting a key enzyme decreases the early development of tumours, their spread to other organs and improves the effectiveness of chemotherapies.
In sub-Saharan Africa, educating the public on sickle cell risk
11/27/2014
Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the...
UCLA scientists discover why patients respond to a life-saving melanoma drug
11/26/2014
UCLA researchers have pioneered a new methodology to predict why some patients battling advanced melanoma respond well or not at all to the new breakthrough drug pembrolizumab (Keytruda).
The immune system against cancer
11/26/2014
Promising clinical responses in patients with various cancer types have recently been achieved with checkpoint blockade immunotherapies, which work by reawakening the immune system's response to...
How does environment-damaged DNA lead to disease?
11/26/2014
Using a technique called time-lapse crystallography, researchers have observed for the first time how the polymerase enzyme inserts nucleotides into strands of DNA.
Why cancer cells grow despite a lack of oxygen
11/26/2014
Healthy cells reduce their growth when there is a lack of oxygen (hypoxia). This makes it even more surprising that hypoxia is a characteristic feature of malignant tumours.
ZS Pharma announces publication of results from phase 3 study of ZS-9 in patients with hyperkalemia
11/26/2014
ZS Pharma have announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM).